Endpoints News
A conversation with the president of Salk Institute Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
6 July, 2026
sponsored by Biotech XYZ
Recruit NYC’s Top Biotech Talent at Biotech XYZ's Inaugural Career Fair
Biotech XYZ's Inaugural Career Fair offers a unique opportunity to connect with a targeted biotech talent pool from across NYC's life sciences community. Recruit for internship and full-time roles, access candidate resume books, increase brand visibility, and engage directly with future biotech leaders through employer booths and industry speaking opportunities.
Complete Interest Form
top stories
1. Bristol Myers details Krazati confirmatory study failure in colorectal cancer
2. Salk Institute’s president on NIH cuts, being ‘all in’ on AI, and the Year of the Brain
3. Roche's $25M Astex deal is small money upfront, but a big signal for breast cancer goals
4. Updated: Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
5.
news briefing
Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot
6. Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
7. After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact
8. Nominations are open for the 2026 Endpoints 11 awards — submit by July 15
more stories
 
Alex Hoffman
.

We're back after the July 4 weekend! The deadline is fast approaching to submit your nominations for our annual Women in Biopharma special report. To add a suggestion for this year's class, please fill out this form by July 10.

.
Alex Hoffman
Copy Chief and News Editor, Endpoints News
1
by Max Gelman

While Amer­i­cans geared up for the Ju­ly 4 hol­i­day, Bris­tol My­ers Squibb laid out how a con­fir­ma­to­ry tri­al for its drug Kraza­ti failed in col­orec­tal...

Read the full story
Gerald Joyce, Salk Institute president (Credit: Salk Institute)
2
by Andrew Dunn

SAN DIEGO — From the pres­i­dent’s of­fice at the Salk In­sti­tute, Ger­ald Joyce has a quin­tes­sen­tial Cal­i­for­nia view of hang glid­ers soar­ing over the Pa­cif­ic Ocean...

Read the full story
Endpoints 11 - Reserve Your Spot
The most differentiated science stays out of public view. This September, the Endpoints newsroom reveals the 11 private companies worth watching, live at the State Room in Boston. See the list first, reserve your spot and save with the early bird rate.
3
by Elizabeth Cairns

Mon­day’s deal be­tween Ot­su­ka’s sub­sidiary As­tex and Roche’s sub­sidiary Genen­tech is of in­ter­est not be­cause it is big mon­ey — the up­front fee is just...

Read the full story
Endpoints webinars
Jul 30
1:00 pm ET
Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights
GUARDANT
4
by Ayisha Sharma

No­var­tis said Mon­day it will be spend­ing $1.1 bil­lion up­front to buy Myricx Bio, which has an ADC pay­load plat­form that could of­fer an edge...

Read the full story
News Briefing: Quick hits from the biopharma web